Elan/Biogen Idec Antegren Will Set Premium Price In Multiple Sclerosis
This article was originally published in The Pink Sheet Daily
Executive Summary
The pricing model anticipates future indications for Antegren, including Crohn’s and rheumatoid arthritis. Current MS therapies Avonex and Rebif are priced at roughly $1,000 and $1,400 per month, respectively.